Trial Title:
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT ID:
NCT02715284
Condition:
Neoplasms
Conditions: Official terms:
Dostarlimab
Conditions: Keywords:
Metastatic solid tumors
Advanced solid tumors
anti-PD-1
TSR-042
Immunotherapy
PD-1
Endometrial
Non-small cell lung cancer, NSCLC
MSI-High
Dostarlimab
dMMR
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Sequential Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Biological
Intervention name:
Dostarlimab
Description:
Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody
that binds with high affinity to PD-1 resulting in inhibition of binding to programmed
death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a
30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional
patients enrolled specifically to better characterize the PK/PDy profile in Part 1,
dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose
administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be
administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days
and Q6W dosing is 42 days.
Arm group label:
Part 1: Participants receiving dostarlimab
Arm group label:
Part 2A: Participants receiving dostarlimab
Arm group label:
Part 2B: Cohort A1 dMMR/MSI-H endometrial cancer
Arm group label:
Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer
Arm group label:
Part 2B: Cohort E NSCLC
Arm group label:
Part 2B: Cohort G PROC without known BRCA
Arm group label:
Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers
Summary:
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the
anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042)
n participants with advanced solid tumors who have limited available treatment options.
The study will be conducted in 2 parts with Part 1 consisting of safety evaluation,
pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab.
Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab
and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at
any dose level up to the highest dose of 20 milligrams per kilograms (mg/kg) based on
emerging safety and PK/PDy data. Part 2 will be conducted in two subparts, Part 2A
(fixed-dose safety evaluation cohorts) and Part 2B (expansion cohorts). Part 2A of the
study will evaluate the safety and tolerability of dostarlimab at fixed doses of 500 mg
administered every 3 weeks (Q3W) and 1000 mg administered every 6 weeks (Q6W). Part 2B of
the study will examine the safety and clinical activity of dostarlimab in cohorts of
participants with specific types of advanced solid tumors.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Participant is at least 18 years of age.
- Participant has proven recurrent or advanced solid tumor and has disease progression
after treatment with available anti cancer therapies, or is intolerant to treatment
that meets the following requirements for the part of the study they will
participate in:
- a. Part 1: Any histologically or cytologically proven recurrent advanced solid tumor
- b. Part 2A: : Any histologically or cytologically proven recurrent advanced solid
tumor
- c. Part 2B: Histologically of cytologically proven recurrent or advanced solid tumor
with measurable lesion(s) per RECIST version 1.1 and meets one of the following
disease types:
- The criteria below should be met for participant participating in: Cohort A1
(dMMR/MSI-H endometrial cancer) and Cohort A2 (MMR-proficient/MSS endometrial
cancer)
- Participants who have progressed on or after platinum doublet therapy
- Participants have received no more than 2 lines of anti-cancer therapy for recurrent
or advanced (>=Stage IIIB) disease. Prior treatment with hormone therapies is
acceptable and does not count towards the number of anti-cancer therapies noted in
the criterion above for this cohort.
- All endometrial cancer histologies are allowed except endometrial sarcoma (including
carcinosarcoma).
- Participants must submit 2 scans demonstrating increase in tumor measurement that
meet criteria for PD on or after the latest systemic anti-cancer therapy based on
RECIST Version 1.1 to Central Radiology prior to the first dose of dostarlimab.
- Presence of at least 1 measurable lesion on Baseline scan will be confirmed by
central radiology review.
- Status of tumor MMR/MSI: Participants can be screened based on local MMR/MSI testing
results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next
generation sequencing (NGS) performed in a certified local laboratory, but
participant eligibility needs to be determined by MMR IHC results. For participant
with available local MMR IHC results for the respective cohort(s), tumor samples
have to be submitted to a central IHC laboratory and its quality has to be checked
and cleared prior to Cycle 1 Day 1 (C1D1). For participants without available local
MMR IHC test results (participants with local PCR or NGS test results), central IHC
results have to confirm eligibility prior to proceeding with other screening
procedures. After the central IHC test is completed, remaining tumor tissue may be
tested for further exploratory biomarkers or may be sent to a central NGS laboratory
for further testing.
- Cohort E - Participants with NSCLC who progressed after at least 1 prior
platinum-based systemic chemotherapy regimen for recurrent or advanced disease.
Chemotherapy regimen in the adjuvant or neoadjuvant setting following surgery and/or
radiation is acceptable if recurrent or advanced disease develops within 6 months
from completion of therapy.
- Participants with a known epidermal growth factor receptor (EGFR) mutation must have
received a chemotherapy regimen and an EGFR tyrosine-kinase inhibitor (TKI) (e.g.,
erlotinib, gefitinib, afatinib, or experimental)
- Participants with a known anaplastic lymphoma kinase (ALK) translocation must have
received a chemotherapy regimen and an ALK inhibitor (e.g., crizotinib, ceritinib or
experimental)
- Cohort F - Participants with recurrent or advanced dMMR/MSI-H solid tumors except
endometrial cancers and gastrointestinal cancers, who have received prior systemic
therapy and who have no alternative treatment options. Prior treatment with hormone
therapies alone given for recurrent or advanced disease is acceptable and does not
count towards the number of anti-cancer therapies.
- Measurable lesion by RECIST 1.1 Radiology on baseline scan will be confirmed by
central radiology review prior to first dose of dostarlimab. Patients with primary
CNS tumor should provide brain MRI at baseline.
- a. Presence of deficient mismatch repair (dMMR) and/or microsatellite instability
(MSI-H) in the tumor defined by either:
- b. deficient DNA mismatch repair (dMMR); MMR status must be assessed by
immunohistochemistry (IHC) for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where
loss of one or more proteins indicates dMMR; dMMR may be determined either locally
or by the central reference lab; OR
- c. Microsatelillite instability (MSI-H); MSI-H as determined by polymerase chain
reaction (PCR) or by tissue Next generation sequencing (NGS); MSI-H may be
determined locally
- Cohort G: Participants must have recurrent high-grade serous, endometrioid, or clear
cell ovarian, fallopian tube, or primary peritoneal cancer. Participants must have
presence of at least 1 measurable lesion on Baseline scan that will be confirmed by
central radiology review.
- Participants must be considered resistant to the last administered platinum therapy,
that is, the time from the last administered platinum dose until the initial
documented progression (as evidenced by radiographic progression per RECIST version
1.1) must be less than 6 months.
- Participants must have completed at least 1 but no more than 3 prior lines of
therapy for advanced or metastatic ovarian cancer. Neoadjuvant, adjuvant, and the
combination of both will be considered as 1 line of therapy. Treatment with
single-agent bevacizumab given as maintenance is not counted as a separate line of
therapy. If a therapeutic regimen is modified or changed for a reason other than
lack of response or PD (such as allergic reaction, toxicity, or drug availability),
this is not counted as a separate line of therapy. The use of single-agent hormonal
therapy given for reasons other than PD per RECIST version v1.1 (i.e., hormonal
therapy given for increasing Cancer antigen [CA]-125 levels) is not counted as a
separate line of therapy.
- Participants must have been previously treated with platinum-based regimen, taxane
agent(s), and bevacizumab (bevacizumab could be used as a single agent or in
combination with another agent, in frontline therapy, as maintenance, or for
treatment of recurrent disease).
- Part 2B: Participants must have archival tumor tissue available that is
formalin-fixed and paraffin-embedded (FFPE).
- For participants who do not have archival tissue, a new biopsy must be performed to
obtain a tissue sample prior to study treatment initiation. For participants without
available archival tissue, the biopsy should be taken from the tumor lesions (either
primary or metastatic) that have easy accessibility and low biopsy-associated risks
and will exclude biopsies of the liver, brain, lung/mediastinum, pancreas, or
endoscopic procedures extending beyond the esophagus, stomach or bowel.
- For Cohort F an FFPE tissue sample must be submitted to the central laboratory for
testing. For patients with available local MMR/MSI-H results, tumor samples have to
be submitted to a central laboratory and its quality has to be checked and cleared
prior to C1D1
- For Cohort G, participant must provide formalin fixed paraffin embedded (FFPE) tumor
tissue block(s) with sufficient tumor content (as confirmed by the Sponsor's
designated central laboratory) during screening to enable, for example, measures of
homologous recombination pathway defects and PD-L1 status. The use of slides created
from paraffin-embedded tissue as opposed to FFPE blocks must be approved by the
Sponsor.
- Female participants must have a negative serum pregnancy test within 72 hours prior
to the date of the first dose of study medication: unless they are of non-child
bearing potential.
- Non child bearing potential is defined as: >= 45 years of age and has not had menses
for > 1 year; Amenorrheic for < 2 years without a hysterectomy and oophorectomy and
have a follicle- stimulating hormone (FSH) value in the postmenopausal range upon
pre-study (screening) evaluation. Post-hysterectomy, post-bilateral oophorectomy, or
post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with
medical records of the actual procedure or confirmed by an ultrasound, magnetic
resonance imaging (MRI) or computed tomography (CT) scan. Tubal ligation must be
confirmed with medical records of the actual procedure.
- Female participants of childbearing potential must agree to use 1 highly effective
form of contraception with their partner starting with the screening visit through
150 days after the last dose of study therapy.
- Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of
<= 2 for Part 1 and <= 1 for Part 2.
- Participant has an adequate organ function.
Exclusion Criteria
- Participant has received prior therapy with an anti- programmed death receptor 1
(anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2)
agent.
- Participant has a known uncontrolled central nervous system (CNS) metastases and/or
carcinomatous meningitis.
- Participant has a known additional malignancy that progressed or required active
treatment within the last 2 years. Exceptions include basal cell carcinoma of the
skin, squamous cell cancer (SqCC) of the skin that has undergone potentially
curative therapy, or in situ cervical cancer, or other neoplastic condition which
has undergone curative therapy and is considered cured by the investigator.
- Participant is considered a poor medical risk due to a serious, uncontrolled medical
disorder, nonmalignant systemic disease or active infection requiring systemic
therapy. Specific examples include, but are not limited to, active, non-infectious
pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial
infarction; uncontrolled major seizure disorder; unstable spinal cord compression;
superior vena cava syndrome; or any psychiatric or substance abuse disorders that
would interfere with cooperation with the requirements of the study (including
obtaining informed consent).
- Participant is pregnant or breastfeeding, or expecting to conceive children within
the projected duration of the study, starting with the Screening Visit through 150
days after the last dose of study treatment.
- Participant has a diagnosis of immunodeficiency or is receiving systemic steroid
therapy or any other form of immunosuppressive therapy within 7 days prior to the
first dose of study treatment.
- Participant has a known history of human immunodeficiency virus (HIV) (HIV 1/2
antibodies).
- Participant has a known active hepatitis B (eg, hepatitis B surface antigen [HBsAg]
reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid (HCV RNA)
(qualitative) is detected).
- Participant has an active autoimmune disease that has required systemic treatment in
the past 2 years (i.e., with use of disease- modifying agents, corticosteroids, or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment. Use of inhaled
steroids, local injection of steroids, and steroid eye drops are allowed.
- Participant has as history of interstitial lung disease.
- Participant has not recovered (i.e., to <= Grade 1 or to Baseline) from radiation-
and chemotherapy-induced AEs or received transfusion of blood products (including
platelets or red blood cells) or administration of colony-stimulating factors
(including granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage
colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 3 weeks
prior to the first dose of study drug.
- Participant has participated in a study of an investigational agent and received
study therapy or used an investigational device within 4 weeks prior to the first
dose of study drug.
- Participant has received prior anti-cancer therapy (chemotherapy, targeted
therapies, radiotherapy, or immunotherapy) within 21 days, or less than 5 times the
half-life of the most recent therapy prior to study Day 1, whichever is shorter.
- Participant has not recovered adequately (<= Grade 1) from AEs and/or complications
from any major surgery prior to starting therapy.
- Participant has received a live vaccine within 14 days of planned start of study
therapy.
- Participant has a known hypersensitivity to dostarlimab components or excipients.
- For Cohort G, participants will not be eligible if they meet the following criteria:
Participants who experienced disease progression within 3 months (as evidenced by
radiographic progression per RECIST) of first-line platinum therapy.
- Participants with known deleterious or suspicious deleterious mutation in BRCA1 or
BRCA2 genes (local testing permitted).
- Participants has received prior therapy with a poly(adenosine diphosphate-ribose)
polymerase (PARP)-1/PARP-2 inhibitor.
- Participant has a history or current evidence of any condition, therapy, or
laboratory abnormality that might confound the results of the study, might interfere
with the participant's participation for the full duration of the study treatment,
or is not in the best interest of the participant to participate.
- Participant is immunocompromised. Participants with splenectomy are allowed.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
GSK Investigational Site
Address:
City:
Birmingham
Zip:
35233
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Goodyear
Zip:
85338
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Phoenix
Zip:
85054
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Scottsdale
Zip:
85258
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Fayetteville
Zip:
72703
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Encinitas
Zip:
92024
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
La Jolla
Zip:
92093
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Los Angeles
Zip:
90095
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Newport Beach
Zip:
92663
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Orange
Zip:
92868
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
San Francisco
Zip:
94115
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
San Marcos
Zip:
92069
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Santa Monica
Zip:
90403
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Washington
Zip:
20007
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Jacksonville
Zip:
32224
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Miami
Zip:
33136
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Tampa
Zip:
33612
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Atlanta
Zip:
30322
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Augusta
Zip:
30912
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Chicago
Zip:
60637
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Chicago
Zip:
60637
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Gini F Fleming
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Westwood
Zip:
66205
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Scarborough
Zip:
04074
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Baltimore
Zip:
21231
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Boston
Zip:
02114
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Boston
Zip:
02215
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Boston
Zip:
02215
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Detroit
Zip:
48201
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Rochester
Zip:
55905
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Kansas City
Zip:
64111
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Farmington
Zip:
87401
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Sardar Imam
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Albany
Zip:
12208
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Brooklyn
Zip:
11203
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Jamaica
Zip:
11432
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
New York
Zip:
10016
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
New York
Zip:
10016
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Bhavana Pothuri
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
New York
Zip:
10032
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Charlotte
Zip:
28204
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Cleveland
Zip:
44106
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Columbus
Zip:
43210
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Columbus
Zip:
43210
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
David O Malley
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Hilliard
Zip:
43026
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
David O Malley
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Oklahoma City
Zip:
73104
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Portland
Zip:
97239
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Philadelphia
Zip:
19104
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Philadelphia
Zip:
19111
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Providence
Zip:
02905
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Nashville
Zip:
37232-7415
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Dallas
Zip:
75230
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Dallas
Zip:
75290-9032
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Matthew Carlson
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Dallas
Zip:
75290-9032
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Houston
Zip:
77030
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
San Antonio
Zip:
78229
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
San Antonio
Zip:
78229
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Salt Lake City
Zip:
84112
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Charlottesville
Zip:
22903
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Seattle
Zip:
98104
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Seattle
Zip:
98195
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Spokane
Zip:
99202
Country:
United States
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Spokane
Zip:
99202
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Spokane
Zip:
99204
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Melanie K Bergman
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Morgantown
Zip:
26506-9260
Country:
United States
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Milwaukee
Zip:
53226
Country:
United States
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Ciudad Autonoma de Buenos Aires
Zip:
C1280AEB
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Ernesto Korbenfeld
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Florida
Zip:
B1602DQD
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Gustavo Alberto Lopez
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Ciudad de Córdoba
Zip:
X5004FHP
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Córdoba
Zip:
X5000HXL
Country:
Argentina
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Porto Alegre
Zip:
90035-000
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Fabio Andre Franke
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Barretos
Zip:
14784-400
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Dayana Mendes Ribeiro
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Ribeirao Preto
Zip:
14040-030
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Liane Rapatoni
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Sao Jose Do Rio Preto
Zip:
15090-200
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Rio de Janeiro
Zip:
20231-050
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
João Tadeu Fidelis Junior
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Sao Paulo
Zip:
01246-000
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Camila Moniz
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
São Paulo
Zip:
01321-001
Country:
Brazil
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Fernando Maluf
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Calgary
Zip:
T2N 4N2
Country:
Canada
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Edmonton
Zip:
T6G 1Z2
Country:
Canada
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Kelowna
Zip:
V1Y 5L3
Country:
Canada
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Susan Ellard
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Vancouver
Zip:
V5Z 4E6
Country:
Canada
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Hamilton
Zip:
L8V 5C2
Country:
Canada
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
London
Zip:
N6A 4L6
Country:
Canada
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Stephen Welch
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Montreal
Zip:
H2L 4M1
Country:
Canada
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Vanessa Samouelian
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Montreal
Zip:
H4A 3J1
Country:
Canada
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Horovice
Zip:
26831
Country:
Czechia
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Zlin
Zip:
762 75
Country:
Czechia
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Copenhagen
Zip:
DK- 2100
Country:
Denmark
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Odense
Zip:
5000
Country:
Denmark
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Bordeaux Cedex
Zip:
33076
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Caen Cedex 05
Zip:
14076
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Dijon
Zip:
21000
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Francois Ghiringhelli
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Lille
Zip:
59000
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Marseille Cedex 9
Zip:
13273
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Paris cedex 12
Zip:
75571
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Paris Cedex 15
Zip:
75908
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Yann-Alexandre Vano
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Saint-Herblain
Zip:
44805
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Villejuif Cedex
Zip:
94805
Country:
France
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Napoli
Zip:
80131
Country:
Italy
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Modena
Zip:
41100
Country:
Italy
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Stefano Cascinu
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Roma
Zip:
00144
Country:
Italy
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Milano
Zip:
20132
Country:
Italy
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Milano
Zip:
20133
Country:
Italy
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Milano
Zip:
20141
Country:
Italy
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Verona
Zip:
37134
Country:
Italy
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
MIlano
Zip:
20133
Country:
Italy
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Gwangju
Zip:
61469
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Taek Won Kang
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Incheon
Zip:
21565
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Sun-Jin Sym
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Seongnam si
Zip:
463 707
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Kidong Kim
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Seongnam
Zip:
463-712
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Min Chul Choi
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Seoul
Zip:
02841
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Jae-yun Song
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Seoul
Zip:
05505
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Seoul
Zip:
06591
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Ji Youl Lee
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Suwon
Zip:
16247
Country:
Korea, Republic of
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Byoung Yong Shim
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Mexico
Zip:
06760
Country:
Mexico
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Monterrey
Zip:
66278
Country:
Mexico
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Servando Cardona-Huerta
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Cordoba
Zip:
94560
Country:
Mexico
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Jose David Gomez-Rangel
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Veracruz
Zip:
91900
Country:
Mexico
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Erika Castillo-Gutierrez
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Gdynia
Zip:
81-519
Country:
Poland
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Lublin
Zip:
20-090
Country:
Poland
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
Lublin
Zip:
20081
Country:
Poland
Status:
Withdrawn
Facility:
Name:
GSK Investigational Site
Address:
City:
Olsztyn
Zip:
10-513
Country:
Poland
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Malgorzata Suszko-Kazarnowicz
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Olsztyn
Zip:
10-561
Country:
Poland
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Torun
Zip:
87-100
Country:
Poland
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Piotr Sawrycki
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Warszawa
Zip:
02-781
Country:
Poland
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Barcelona
Zip:
08036
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Barcelona
Zip:
08907
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Barcelona
Zip:
8035
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Córdoba
Zip:
14004
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Juan de la Haba
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Girona
Zip:
17007
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Hospitalet de Llobregat (Barcelona)
Zip:
08907
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Jaén
Zip:
23007
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Ana Laura Ortega Granados
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Lerida
Zip:
25198
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Serafin Morales Murillo
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Madrid
Zip:
28027
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Madrid
Zip:
28040
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Madrid
Zip:
28040
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Victor Moreno Garcia
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Madrid
Zip:
28046
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Madrid
Zip:
28050
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Valentina Boni
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Murcia (El Palmar)
Zip:
30120
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Málaga
Zip:
29010
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Pamplona
Zip:
31008
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Salvador Martín Algarra
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Santander
Zip:
39008
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Ignacio Durán Martínez
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Santiago de Compostela
Zip:
15706
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Sevilla
Zip:
41013
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Manuel Valladares Ayerbes
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Valencia
Zip:
46009
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Valencia
Zip:
46010
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Zaragoza
Zip:
50009
Country:
Spain
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Aberdeen
Zip:
AB25 2ZN
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Headington, Oxford
Zip:
OX3 7LE
Country:
United Kingdom
Status:
Completed
Facility:
Name:
GSK Investigational Site
Address:
City:
London
Zip:
SE1 9RT
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
London
Zip:
SW3 6JJ
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
London
Zip:
SW36JJ
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
London
Zip:
W1G 6AD
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
London
Zip:
W1T 7HA
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Manchester
Zip:
M20 4BX
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Facility:
Name:
GSK Investigational Site
Address:
City:
Newcastle upon Tyne
Zip:
NE7 7DN
Country:
United Kingdom
Status:
Recruiting
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Yvette Drew
Email:
Principal Investigator
Start date:
March 7, 2016
Completion date:
October 27, 2027
Lead sponsor:
Agency:
Tesaro, Inc.
Agency class:
Industry
Source:
Tesaro, Inc.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT02715284
